<WIRE> Imugene (ASX:IMU) Experiences Significant Fall Following Discounted Share Placement

Imugene’s share prices have fallen by 14.9% to A$0.080, marking a near three-year low for the Australian biopharma company.

This fall has occurred in conjunction with the completion of a A$35 million share placement, with shares issued at A$0.084 each.

The stock, which has already fallen by 35.2% this year, is now set for its worst trading day since October 2022 due to this share issue price, which reflects a 10.6% discount to the last closing price.

Imugene is a clinical-stage immune-oncology firm, focused on creating high-performing immuno therapies for cancer patients.

View full chart on Save $30 on a Pro or Premium TradingView account

Save $30 on a Pro or Premium TradingView account

Supported by

<SPON> Trade share CFDs with Plus500

Global online trading services company, Plus500:

Plus500 trading platform allows you to trade shares from all popular markets such as USA, UK, Germany and more, with leverage and low spreads. Using our advanced trading tools, you can also control your profits and losses.

Plus500AU Pty Ltd, AFSL #417727 issued by Australian Securities and Investments Commission. Based in Sydney.


Subscribe to the newsletter

Receive whispers every day in your inbox.